Fig. 2
Modulating TNFRs selectively does not lead to major changes in leukocytes subsets. Hu/m TNFR1-ki x hu/m TNFR2-ki mice treated either with saline, EHD2-scTNFR2 (TNFR2 agonist), ATROSIMAB (TNFR1 antagonist) or a combination (E + A) were killed either 18 (acute) or 25 (chronic) days post-immunization (dpi; n = 3–5 animals/treatment group/killing timepoint). Immune cells from inguinal lymph nodes (on the left) and spleen (on the right) were analyzed by flow cytometry to reveal the frequencies of CD3 + T cells (A and B), CD19 + B cells (C and D), CD3 + FoxP3 + Treg (E and F) and CD3 + CD8 + IFN-γ + cytotoxic T cells (G and H). Representative contour plots depict interferon gamma (IFN-γ) expression of CD8 + T cells in spleen samples from animals killed at 18 dpi (I). The percentage of CD3 + CD8 + IFN-γ + cells is reported at the bottom right of each plot. Data are presented as mean ± SEM and differences between groups were assessed with one-way ANOVA and Tukey’s post-test. *p < 0.05, **p < 0.01